Commercial anti‐CD19 CAR T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center

Sesques, Pierre; Ferrant, Emmanuelle; Safar, Violaine; Wallet, Florent; Tordo, Jérémie; Dhomps, Anthony; Karlin, Lionel; Brisou, Gabriel; Vercasson, Marlène; Schwiertz, Vérane; Ranchon, Florence; Rioufol, Catherine; Choquet, Marion; Sujobert, Pierre; Ghergus, Dana; Bouafia, Fadhela; Golfier, Camille; Lequeu, Hélène; Lazareth, Anne; Novelli, Silvana; Devic, Perrine; Traverse Glehen, Alexandra; Viel, Sébastien; Venet, Fabienne; Mialou, Valérie; Héquet, Olivier; Chauchet, Adrien; Arkam, Yazid; Nicolas‐Virelizier, Emmanuelle; Peyrade, Frédéric; Cavalieri, Doriane; Ader, Florence; Ghesquières, Hervé; Salles, Gilles; Bachy, Emmanuel

doi:10.1002/ajh.25951

Public

Commercial anti‐CD19 CAR T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center

Published in American Journal of Hematology • Aug 3, 2020

Authors:

Pierre Sesques

Emmanuelle Ferrant

Violaine Safar

Abstract

Two autologous anti-CD19 chimeric antigen receptors (CAR) T cells (axicabtagene ciloleucel [axi-cel] and tisagenlecleucel [tisa-cel]) are commercially approved in Europe for relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL). We performed a retrospective study to evaluate patterns of us...

Subject

Medicine

Cytokine release syndrome

Refractory (planetary science)

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!